{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026343","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.032395+00:00","generated_at":"2026-06-12T11:12:04.888109+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Interpace Biosciences appoints Christopher McCarthy as CFO effective July 24, 2023","bullets":["McCarthy previously served as Principal Financial Officer since April 2023; base salary set at $220,000.","Eligible for annual bonus target up to 40% of base salary; received RSU grant of 25,000 shares (12,500 vested immediately, remainder in 6 months).","Additional 25,000 RSUs to be granted on July 27, 2024, fully vested on grant date.","Severance of 6 months base salary plus COBRA premiums for 6 months upon termination without cause or for good reason, subject to release.","Employment is at-will; no family relationships or related party transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026343","json":"https://secwatch.observer/filing/0001493152-23-026343.json","markdown":"https://secwatch.observer/filing/0001493152-23-026343.md","text":"https://secwatch.observer/filing/0001493152-23-026343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/0001493152-23-026343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:12:04.888109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6210dc772f","claim":"Christopher McCarthy was appointed as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..","evidence_excerpt":"On July 24, 2023, the Board of Directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”) appointed Christopher McCarthy, age 32, as Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223026343/0001493152-23-026343-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}